State of Melanoma: An Historic Overview of a Field in Transition.
Hematol Oncol Clin North Am
; 35(1): 1-27, 2021 02.
Article
em En
| MEDLINE
| ID: mdl-33759768
ABSTRACT
The management of melanoma significantly improved within the last 25 years. Chemotherapy was the first approved systemic therapeutic approach and resulted in a median overall of survival less than 1 year, without survival improvement in phase III trials. High-dose interferon α2b and IL-2 were introduced for resectable high-risk and advanced disease, respectively, resulting in improved survival and response rates. The anti-CTLA4 and anti-programmed death 1 monoclonal antibodies along with BRAF/MEK targeted therapies are the dominant therapeutic classes of agent for melanoma. This article provides an historic overview of the evolution of melanoma management.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Cutâneas
/
Melanoma
/
Antineoplásicos
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article